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The proliferation of commercially-available 
"kits" for the clinical laboratory has resulted in such 
a technological surfeit that one or more kits are 
available for virtually every type of commonly per-
formed test. Such kits offer prepackaged convenience 
and, under some circumstances, economies in the 
laboratory. A few offer technical procedures which 
are superior to standard methods. 
In spite of their apparent simplicity, commercial 
availability of a reagent kit does not provide any as-
surance that it will perform satisfactorily or that the 
resulting data will be accurate. In contrast to thera-
peutic agents, federal regulation of the manufacture 
of diagnostic kits has only recently been instituted, 
and it remains for the user to determine whether a 
particular kit does in fact meet the specifications 
stated in promotional material. The selection and the 
continuing evaluation of diagnostic kits present prob-
lems to every laboratory, whether the laboratory is 
in the physician's office or in a large hospital. 
Perhaps the simplest type of kit is a prepared 
reagent for a certain determination. This category 
would include specific antisera for blood grouping or 
other purposes, as well as standard chemical rea-
gents. Usually, however, the word "kit" is used to 
describe a prepackaged set of multiple reagents for 
carrying out a certain test in the laboratory. Many 
such multiple-reagent kits are based upon standard, 
accepted methods; those from reliable manufacturers 
offer the advantages of standard methodology and 
elimination of reagent preparation. Some kits are 
based upon manufacturer-developed methods which 
are usually patented or kept as proprietary secrets. 
Some of these manufacturer-developed methods are 
acceptable; some, no doubt, have been developed 
primarily to permit a wider profit margin. Lastly, 
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several well-known firms are marketing kits which 
are suitable only for their own analytical instru-
ments. This presents a double dilemma for the pur-
chaser, since it is necessary not only to evaluate the 
kit but the instrument as well. 
Selection of Kits. Most physicians are deluged 
with flyers and advertisements which suggest that the 
purchase of a few kits is an efficient and entirely 
satisfactory method of installing an instant clinical 
laboratory. These blandishments frequently lead to an 
illogical and expensive system for providing labora-
tory data. The first question to be asked is not which 
kits to buy but rather which determinations should 
be done in the laboratory. If a test is definitely 
needed, purchase of a kit is one of the alternative 
methods for making it available. Particularly in the 
physician's office, the convenience, the elimination 
of reagent preparation and savings in personnel time 
are advantageous. Use of a kit usually results in a 
higher per-test cost than having the test done in a 
large, automated laboratory, but the advantages of 
using kits sometimes outweigh these higher costs. 
Kits from different manufacturers will offer different 
analytical methods, differing numbers of tests per kit, 
different instrument requirements and, of course, dif-
ferent prices. 
An important principle in selecting any type of 
laboratory kit is to require the manufacturer to pro-
vide relevant experimental data which substantiate 
any claims regarding performance of the kit. Descrip-
tions such as accurate, precise, simple, inexpensive 
and reliable are all relative. Unless the manufacturer 
can produce data, preferably substantiated by an in-
dependent investigator, regarding these parameters 
of performance, further consideration of using the 
kit should not be entertained. Most reputable manu-
facturers will supply reprints of articles describing 
such evaluations. 
Evaluation of Kits. If a laboratory is to produce 
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reliable data, a critical evaluation of each method 
must be carried out prior to its introduction as a 
routine procedure. It is immaterial whether or not 
the procedure utilizes a prepackaged kit. Such an 
evaluation should make full use of any data collected 
by other laboratories, but an experimental evaluation 
by the laboratory which is to use the kit is essential. 
Although kits come in various forms, there are 
two major categories of laboratory tests for which 
they will be used-qualitative tests and quantitative 
tests. Qualitative tests are those for which the results 
can be expressed as a yes or no, positive or negative 
or present or absent report. Pregnancy tests and tests 
for urinary glucose are examples of qualitative tests. 
Quantitative tests are those which are used for mea-
surement of a specific constituent and results are 
expressed in numerical terms. The evaluation of a 
kit will differ depending on whether it is used for a 
qualitative or quantitative procedure. 
Comparison with Reference Method. Evalua-
tion, no matter what is being evaluated, is a com-
parative process. If a kit merely supplies reagents 
necessary to do a standard laboratory test, data on 
the standard test are readily available in published 
form. More often, the kit will be a modification of a 
standard method or, occasionally, a new approach 
to measuring the same constituent. In either situa-
tion, the manufacturer should provide experimental 
data which compare the kit procedure to an ac-
cepted, established method. 
For quantitative tests, the parameters which 
should be examined are accuracy, precision and 
range of linearity over which measurements can be 
made. Accuracy is an elusive parameter to evaluate, 
and a comparison of results using the kit with those 
obtained by a standard method is acceptable. Pre-
cision can be evaluated by replicate determinations 
and linearity by measuring a series of samples with 
varying concentrations of the constituent being meas-
ured. An excellent example of such a comparison 
is the study by Barnett, Cash and Junghans (2) in 
which cholesterol measurements using 12 different 
kits were compared to those using the Abell-Kendall 
method. They concluded that only two of the 12 
kits being marketed at the time of the study were 
acceptable for clinical use . Other published evalua-
tions should be equally disconcerting to any labora-
tory which uses a kit without first subjecting it to 
rigorous performance trials. Kim, Waddell and 
Logan ( 6) measured sodium and potassium with 
chemical kits manufactured by the Stanbio Laborn-
351 
tory, San Antonio, Texas and by Medi-Chem, Santa 
Monica, California. Results were compared with 
those obtained by standard flame photometric tech-
niques, and the authors concluded that both kits 
gave "diagnostically unsatisfactory results." A study 
by Dietz, Rubenstein and Lubrano (5) which in-
volved serum cholinesterase measurements using the 
Acholest® kit manufactured by E. Fougera and Co., 
Hicksville, New York, provides a shocking indict-
ment of the lax standards set by some commercial 
firms. The Acholest® method "failed to detect 12 of 
20 cases at high risk of prolonged apnea after suc-
cinylcholine." Similar comparative studies of kits for 
less complicated procedures such as glucose and urea 
indicate that some are entirely suitable for these 
measurements (7, 9, 11) . It is noteworthy that 
Logan, Waddell and Krynski (9) found that the 
kits which were the most expensive and which re-
vealed the least information concerning their con-
stitution gave the poorest performances. 
The evaluation of comparative data for qualita-
tive tests frequently is more difficult than for quan-
titative tests . The two parameters corresponding to 
accuracy and precision are validity and reproduci-
bility. Reproducibility can be studied through re-
plicate tests on the same group of samples; validity, 
however, like accuracy, may have to be evaluated 
by comparison with a reference method. The objec-
tive for all qualitative tests is a positive result when 
the constituent or disease is present and a negative 
result when it is not. For example, serological tests 
for syphilis are usually compared to the fluorescent 
treponemal antibody-absorbed (FTA-ABS) test. 
Since the serological test is used primarily as a 
screening procedure, acceptable performance would 
result in no false negatives and as few false positives 
as possible. Frequently, the evaluation must include 
consideration of the clinical context in which the 
test will be used. Tests for pregnancy are usually 
evaluated by testing large numbers of pregnant and 
nonpregnant women. A test which gave positive 
results in 97 % of women in the second trimester 
of pregnancy clearly would not be as useful as one 
which gave similar accuracy during the first three 
weeks. The undesirability of false positive pregnancy 
tests is readily apparent. 
In addition to comparisons with reference 
methods, information provided by the manufacturer 
should include predisposing test conditions or pa-
tient abnormalities which will affect the test and give 
inaccurate or undependable results. Such interfering 
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conditions are particularly troublesome with newly 
developed tests such as radioimmunoassays. Tests for 
digoxin, for example, may measure not only digoxin 
but also its metabolites ( 10) . More worrisome, how-
ever, are reports that therapeutically administered 
compounds such as cortisol and spironolactone may 
react with the digoxin-binding antibody to give er-
roneous results. 
Laboratory Trials. Although few laboratories 
will carry out an evaluation of a kit as elaborate 
as those which are described in scientific journals, it 
is falacious to assume that results similar to those in 
published articles can be obtained automatically by 
any kit purchaser. The procedures for experimental 
evaluation may vary from kit to kit, but critical 
testing of every type of kit by the laboratory in which 
it is to be used is essential. 
Meticulous examination of the instructions 
which accompany the kit will frequently eliminate 
unnecessary work. The instructions should present 
a logical and detailed outline of each step in the 
procedure, with a clear indication of where errors 
might occur, what types of instruments are suitable, 
in which steps timing is critical and how results are 
to be calculated from instrument readings. The in-
structions should be followed compulsively under all 
circumstances. Suitable standards should be included 
with aJI kits for quantitative measurements and the 
standards should have concentrations which span the 
range of clinically useful measurements. Controls 
should be run with each batch of any procedure, 
whether it is a quantitative or a qualitative one and, 
if possible, control solutions should be obtained from 
a manufacturer other than the supplier of the kit. 
Qualitative tests generally should have both a positive 
and a negative control; these usually accompany the 
kit, however, since they may be the only suitable 
controls available. 
Replicate determinations on different days of 
one, or preferably several, control solutions provides 
an indication of the precision which might be ex-
pected. If reproducibility is unsatisfactory, the prob-
lem may reside either in the kit or in the technique. 
If errors can be traced to faulty technique which is 
corrected, the experiments should be repeated ; if not, 
the kit should not be accepted for routine use in the 
laboratory. A second useful step in evaluating a kit 
is separation of patient samples into two aliquots, 
one to be run by the kit method and the other to be 
submitted to a reference laboratory. A minimum of 
a dozen, and preferably several times that number, 
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split samples should be analyzed before acceptance 
of the kit for routine use. Many manufacturers will 
supply free samples of kits for preliminary evalua-
tion; this practice, however, should have no influence 
on the laboratory in regard to which kits are tested 
and which are finally selected for routine use. 
Evaluation of an instrument which is designed 
for use with kits for a variety of procedures may be 
quite time-consuming, since each procedure for 
which a kit is available must be evaluated separately. 
Logan and Sunderland ( 8) evaluated the Unitest 
System® marketed by Bio-Dynamics, Inc., In-
dianapolis, Indiana, and Diagnotest® marketed by 
Dow Chemical Company, Diagnostic Products Di-
vision, Indianapolis, Indiana. For each instrument, 
some of the kits performed unsatisfactorily, and the 
authors concluded that personnel without technical 
training could not obtain reliable data with either 
system. 
Continuing Evaluation. Initial evaluation and 
acceptance of a kit for routine use in the laboratory 
does not assure continuing satisfactory performance. 
Most important, the use of kits does not obviate 
the need for strict quality control measures. Suitable 
quality control solutions should be run with each 
batch of procedures, strict limits for variation of the 
control solution should be set and all data should 
be rejected if control readings are out of the pre-
determined range. Lot numbers of each reagent or 
kit should be entered into the laboratory log book 
and when a new lot number is used, samples should 
be run in duplicate with the old and the new reagents 
to permit comparison between lots. 
FDA Regulations Regarding Kits. It perhaps 
should be stressed that most of the laboratory kits 
on the market today were developed during a period 
when there were no federal regulations setting mini-
mum performance standards. As early as 1966 the 
American Association of Clinical Chemists (1) pub-
lished policies regarding reagent sets and kits which, 
had they been followed by all manufacturers, might 
have greatly reduced the number of subsequent 
articles devoted to documenting the inadequacies of 
many kits. Manufacturers also could voluntarily 
submit kits to the College of American Pathologists 
for evaluation; however, compliance with the recom-
mendations of the college in the case of inadequate 
kits was also voluntary. Published evaluations of all 
types of kits clearly indicate that some are unsatis-
factory, some are satisfactory and some are outstand-
ing in meeting performance standards. 
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In January 1972, the Food and Drug Adminis-
tration announced that existing legislation gave them 
authority to exercise regulatory control over diag-
nostic kits to ensure that they deliver a consistently 
high level of quality and performance (3). A state-
ment of procedures for developing policy and inter-
pretive regulations was published in August 1972 
(4). Briefly, these regulations require that diagnostic 
kits be accurate and reliable, that manufacturers test 
and evaluate kits prior to marketing them and verify 
results against a generally accepted procedure, that 
premarket testing is done to find if predisposing 
patient abnormalities will affect the test and that the 
labeling of all kits contains adequate directions for 
use. The labeling directions must include complete 
information on accuracy, reproducibility and sensi-
tivity performance. The FDA intends to establish 
standards of performance for each type of laboratory 
kit and require manufacturers to meet these stand-
ards. Establishing pertinent standards will be time 
consuming (the FDA intends to start with glucose 
and hemoglobin), but merely requiring manufac-
turers to provide evidence that kits will perform as 
claimed will be helpful for anyone who must decide 
which kit to purchase. The FDA is already enforc-
ing these regulations and has required two manufac-
turers of pregnancy test kits to recall their products. 
Cost Evaluation. The cost of performing lab-
oratory tests is causing increasing concern because of 
the dramatic increase in the use of laboratory data in 
patient care and because many of the newer tests are 
more complicated and thus more expensive. Evalua-
tion of a laboratory procedure should include the 
cost of doing it. In a physician's office or a small 
laboratory, such cost accounting can be quite simple, 
since it is easy to calculate the cost per test done by 
a kit method and to measure personnel time in-
volved. Since most kits have expiration dates, the 
cost per test of the kit should take into account the 
necessity for discarding outdated reagents. Generally 
speaking the cost of a quantitative measurement 
carried out by a kit method will be considerably 
higher than the same test carried out on automated 
laboratory instruments. On the other hand, even 
large laboratories use prepared reagents and kits for 
performing some of the simpler tests and these tests 
can be performed in the office laboratory at the same 
or perhaps lower cost than in a large laboratory. 
Higher costs for performing tests in physicians' of-
fices may be offset by convenience to the patient or 
the necessity for having data immediately available. 
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Summary. Prepackaged laboratory kits for per-
forming diagnostic procedures are frequently the 
most suitable alternative in the selection of labora-
tory methods, especially in physicians' offices and 
small laboratories. Because of the previous lack of 
governmental regulations covering the manufacture 
of kits, many kits now on the market do not perform 
adequately and may produce misleading results. 
Each laboratory must evaluate each type of kit 
before it is put into routine use. This evaluation 
should include a review of published experimental 
data, comparison of results using the kit to results 
using a reference method and an experimental 
evaluation of the kit in the laboratory in which it is 
to be used. 
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